Sign up USA
Proactive Investors - Run By Investors For Investors

Amarin shares soar after fish oil tablet pares back risks of heart disease in trial

The Reduce-It study was examining Vascepa’s utility as an additional therapy used by patients with heart problems who were already taking statins
heart with stethoscope
Patients who took Vascepa showed a 25% relative risk reduction of major cardiovascular events compared to those who took a placebo

Shares of Amarin Corporation Plc (NASDAQ:AMRN) are rocketing in Monday’s pre-market session after the Irish biopharmaceutical company reported that its fish oil pill Vascepa greatly reduced risks of cardiovascular disease.

Amarin’s prescription fish oil pill cut back on cardiovascular events when measured against a placebo in a trial, which examined 8,179 adults who were already suffering from heart disease and were being treated with statins.

The results were welcomed by investors, who sent Amarin’s shares up by 314.72% to close on Monday at $12.40, having hit a session top of $12.47. 

Looking at the details, patients enrolled in the trial who took Vascepa showed a 25% relative risk reduction of major adverse cardiovascular events compared to those who took the placebo.

The so-called Reduce-It study was examining Vascepa’s utility as an additional therapy used by patients with heart problems who were already taking statins to address elevated triglyceride levels.

“We are delighted with these topline study results,” said Amarin CEO John Thero in a statement. “Given Vascepa is affordably priced, orally administered and has a favorable safety profile, REDUCE-IT results could lead to a new paradigm in treatment to further reduce the significant cardiovascular risk that remains in millions of patients with LDL-C controlled by statin therapy, as studied in REDUCE-IT.”

Amarin will present additional information from this late-breaking trial at the 2018 Scientific Sessions of the American Heart Association on November 10, 2018 in Chicago, Illinois.

The Reduce it study kicked off in 2011 and was conducted based on a special protocol assessment agreement with the US Food and Drug Administration.

Amarin, which has offices in Bedminster, New Jersey and Dublin, Ireland, focuses on developing therapeutics to improve cardiovascular health. Vascepa, which is its first FDA-approved drug, is available by prescription in the US, Lebanon and the United Arab Emirates.

--Updates share price--

View full AMRN profile View Profile

Amarin Timeline

Related Articles

myLotus kit
August 06 2018
The expansion drive is targeting an estimated 2.3mln women per year in the areas of Hebei, Shanghai, Beijing, Shangdong, Henan and Liaoning
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use